03/10/2025
3:33 PM | Janux Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SCHEDULE 13D/A | |
03/07/2025
5:05 PM | Janux Therapeutics (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/05/2025
7:00 PM | Janux Therapeutics (Issuer)
Meyer Andrew Hollman (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/27/2025
3:53 PM | Janux Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/27/2025
3:55 PM | Janux Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/14/2025
3:41 PM | Janux Therapeutics (Subject)
Paradigm Biocapital Advisors LP (Filed by)
| Form SCHEDULE 13G/A | |
02/14/2025
10:24 AM | JANUS HENDERSON GROUP PLC (Filed by)
Janux Therapeutics (Subject)
| Form SCHEDULE 13G | |
02/12/2025
8:30 AM | Adage Capital Management, L.P. (Filed by)
Janux Therapeutics (Subject)
| Form SCHEDULE 13G | |
02/05/2025
7:00 PM | Janux Therapeutics (Issuer)
Meyer Andrew Hollman (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/08/2025
7:00 PM | Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:11 PM | Campbell David Alan (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for JANX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
01/03/2025
7:00 PM | Janux Therapeutics (Issuer)
McIver Zachariah (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/03/2025
7:01 PM | Janux Therapeutics (Issuer)
Winter Charles M. (Reporting)
| Form 3/A | |
01/03/2025
7:10 PM | Dobek Maria (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2025
7:10 PM | DiRaimondo Thomas (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2025
7:10 PM | Janux Therapeutics (Issuer)
Robinson Byron (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2025
7:10 PM | Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2025
7:10 PM | Janux Therapeutics (Issuer)
Winter Charles M. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2025
7:10 PM | Janux Therapeutics (Issuer)
McIver Zachariah (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/27/2024
7:00 PM | Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/26/2024
9:00 AM | Campbell David Alan (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/20/2024
5:25 PM | Janux Therapeutics (Issuer)
Meyer Andrew Hollman (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/05/2024
3:32 PM | Janux Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/05/2024
3:28 PM | Janux Therapeutics (Filer)
| Form 424B5 | |
12/03/2024
7:00 PM | Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/02/2024
4:10 PM | Janux Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/27/2024
7:00 PM | Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/14/2024
3:24 PM | BIOTECHNOLOGY VALUE FUND L P (Filed by)
Janux Therapeutics (Subject)
| Form SC 13G/A | |
11/08/2024
4:58 PM | Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
| Form SC 13D/A | |
11/07/2024
6:08 PM | CAPPS VICKIE L (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/07/2024
6:09 PM | Gujrathi Sheila (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/06/2024
3:23 PM | Janux Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/06/2024
3:07 PM | Janux Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/01/2024
4:05 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2024
4:02 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2024
3:24 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2024
3:30 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2024
3:17 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2024
3:07 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/30/2024
6:30 PM | Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/28/2024
3:46 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
A brutally honest economic warning for 2025 (see proof) (Ad) New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says.... Full details here. |
10/25/2024
4:28 PM | Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
| Form SC 13D/A | |
10/25/2024
3:57 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/25/2024
3:44 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/25/2024
3:51 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/25/2024
11:37 AM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144/A | |
10/24/2024
4:53 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/24/2024
4:04 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/24/2024
3:15 PM | Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/23/2024
4:59 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2024
4:38 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2024
4:39 PM | Janux Therapeutics (Subject)
Paradigm Biocapital Advisors LP (Filed by)
| Form SC 13G | |
10/23/2024
4:07 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2024
3:36 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/22/2024
3:20 PM | Janux Therapeutics (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:16 PM | Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
| Form SC 13D/A | |
10/22/2024
3:17 PM | Janux Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13D/A | |
10/21/2024
3:43 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/21/2024
3:25 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/21/2024
12:39 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
5:51 PM | Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/18/2024
3:57 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
3:39 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
3:48 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/17/2024
4:06 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/17/2024
3:24 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/17/2024
3:18 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024
5:14 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024
4:35 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024
4:28 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024
4:25 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024
4:17 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024
4:10 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/30/2024
7:49 PM | Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/30/2024
4:29 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/30/2024
4:34 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
6:30 PM | Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/27/2024
6:31 PM | DiRaimondo Thomas (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/27/2024
6:32 PM | Janux Therapeutics (Issuer)
Meyer Andrew Hollman (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/27/2024
5:31 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
4:05 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
3:51 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
3:51 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
3:54 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
3:18 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
3:01 PM | Janux Therapeutics (Subject)
Meyer Andrew Hollman (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
3:05 PM | Campbell David Alan (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/26/2024
4:57 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/26/2024
4:35 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/26/2024
4:13 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/16/2024
8:35 PM | Janux Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13D/A | |
$2 Trillion Disappears Because of Fed's Secretive New Move (Ad) $2 trillion has disappeared from the US government's books.
The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth. Click here to see his new research now. |
09/16/2024
8:41 PM | Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
| Form SC 13D/A | |
09/13/2024
4:01 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
8:18 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
7:54 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
8:07 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
7:42 PM | Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
5:23 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
3:51 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144/A | |
09/11/2024
10:20 AM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144/A | |
